RNS v Proactive interview3 Aug 2015 21:22
http://www.proactiveinvestors.co.uk/companies/news/109385/toumazs-patient-monitoring-technology-set-for-take-off-109385.html
Puzzling that RNS is so negative when CEO so bullish in interview.
Chief executive Anthony Sethill explains.
“SensiumVitals provides the first warning of the deterioration of a patient,” he says. “If you are in a general ward observations currently take place every four-to-six hours. We are reducing it to two minutes.”
That’s quite a considerable improvement and will allow medical staff to intervene at a much earlier stage.
A study conducted at one hospital in America showed that SensiumVitals picked up deterioration in 12% of patients. For these patients, the early warnings provided by SensiumVitals reduced their hospital stay by an average of four days. That works out financially at around US$9,000 per person.
So, not only are the benefits to health very clear, but the financial savings are very considerable.
Indeed, a loose extrapolation of the data reveals that the NHS could save as much as £500 million in ongoing costs if SensiumVitals was implemented, after the product had been paid for.
But introducing a new product into the NHS is a long process, and although a number of leading clinicians already believe SensiumVitals to be of benefit, more trials are needed before the data can be regarded as conclusive.
Those trials are ongoing now.
“A number of trials are underway”, says Sethill. “Worldwide we have about 20 now.”
Included in their number is research going on at St James’s University Hospital, Leeds, and at the Queen Elizabeth Hospital, Birmingham.
Once these trials are complete the opportunity to address the market will be huge, although in the UK Sethill expects there will be a lot of legwork involved selling to individual trusts rather than closing one huge single dea
Sign In
Follow the stocks
